Government-Owned Inventions; Availability for Licensing, 48218-48219 [E8-18984]

Download as PDF 48218 Federal Register / Vol. 73, No. 160 / Monday, August 18, 2008 / Notices Potential applications of this technology may also include detection of Pax-2 protein in urine for both chronic and acute renal disease. Applications: Diagnostics for renal diseases; Research tools for evaluating disease processes of the kidney and other tissues through Pax-2 protein expression in the relevant tissues. Development Status: Ready for commercialization. Patent Status: HHS Reference No. B– 039–1996/0—Research Tool. Patent protection is not being pursued for this technology. Inventor: Gregory Dressler (NICHD). Relevant Publications: 1. GR Dressler. Another niche for Notch. Kidney Int. 2008 Jun;73(11):1207–1209. 2. SR Patel et al. The BRCT-domain containing protein PTIP links PAX2 to a histone H3, lysine 4 methyltransferase complex. Dev Cell. 2007 Oct;13(4):580– 592. 3. GR Dressler. The cellular basis of kidney development. Annu Rev Cell Dev Biol. 2006;22:509–529. 4. GB Silberstein et al. Expression of the PAX2 oncogene in human breast cancer and its role in progesteronedependent mammary growth. Oncogene. 2002 Feb7;21(7):1009–1016. 5. GR Dressler and AS Woolf. Pax2 in development and renal disease. Int J Dev Biol. 1999;43(5):463–468 (Review). 6. GR Dressler. Pax-2, kidney development, and oncogenesis. Med Pediatr Oncol. 1996 Nov;27(5):440–444. 7. GR Dressler and EC Douglass. Pax2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor. Proc Natl Acad Sci USA. 1992 Feb 15;89(4):1179–1183. Licensing Status: Available for nonexclusive licensing as biological materials (internal use or commercial use). Licensing Contact: RC Tang, JD, LLM; 301–435–5031; tangrc@mail.nih.gov. Dated: August 7, 2008. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E8–18983 Filed 8–19–08; 8:45 am] BILLING CODE 4140–01–P sroberts on PROD1PC70 with NOTICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. AGENCY: VerDate Aug<31>2005 16:50 Aug 15, 2008 Jkt 214001 ACTION: Notice. SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Species-Independent A3 Adenosine Receptor Agonists Description of Technology: The A3 adenosine receptor (A3AR) subtype has been linked with helping protect the heart from ischemia, controlling inflammation, and regulating cell proliferation. Agonists of the human A3AR subtype have been described; however, they lack selectivity for the corresponding receptor of the mouse. This poses a problem for clinical development because animal model testing is important for pre-clinical validation of drug function. Consequently, a novel agonist was made that is selective for the mouse A3AR while retaining selectivity for the human receptor. This innovation should facilitate moving A3 agonists into the clinical phase of drug development with confidence. This invention claims speciesindependent agonists of A3AR, specifically (N)-methanocarba adenine nucleosides. In addition, it describes pharmaceutical compositions comprising such nucleosides, and methods of use such as administering an effective amount to a mammal. Applications: cardiac arrhythmias or ischemia; inflammation; stroke; diabetes; asthma; cancer. Market: Heart disease and cancer are the leading causes of death for both women and men in the United States despite many advances in drug development. Hence, there is a need for drugs with unique mechanism of action. It is noteworthy that the first synthetic adenosine receptor agonist has recently been approved for use in humans. PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 Development Status: Research quantities of compounds have been synthesized and tested for receptor selectivity. Inventors: Kenneth A. Jacobson and Artem Melman (NIDDK). Publication: A Melman et al. Design of (N)-methanocarba adenosine 5′uronamides as species-independent A3 receptor-selective agonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2813– 2819. Patent Status: U.S. Provisional Application No. 61/040,985 filed 31 Mar 2008 (HHS Reference No. E–140–2008/ 0–US–01). Licensing Status: Available for exclusive or non-exclusive licensing. Licensing Contact: Norbert Pontzer, J.D., Ph.D.; 301–435–5502; pontzern@mail.nih.gov. Fluorescent Cell Lines for Detection of DNA Damage Description of Technology: The Enhanced Level of Genomic instability 1 (ELG1) protein suppresses genomic instability caused by DNA damage. Cell lines for studying human ELG1 (hELG1) have been established that stably express a fusion protein combining hELG1 and either Green Fluorescent Protein (GFP) or Cyan Fluorescent Protein (CFP). It has been shown that the fluorescent hELG1 is an excellent reporter for DNA damage within the cell, with increased hELG1 localization to the cell nucleus upon exposure to a genotoxin. Therefore, these cell lines may have utility as a screening tool to detect genotoxic agents. Available for licensing are the RPE cell line (immortalized normal retinal pigment epithelial cells) stably expressing hELG1-CFP, and the U2OS cell line (human osteosarcoma cells) stably expressing hELG1-GFP. Applications: High-sensitivity screening tool for genotoxic agents. Inventor: Kyungjae Myung (NHGRI). Relevant Publication: In preparation. Patent Status: DHHS Reference No. E– 108–2008/0—Research Tool. Patent protection is not being pursued for this technology. Licensing Status: Available for nonexclusive licensing. Licensing Contact: Tara L. Kirby, Ph.D.; 301–435–4426; tarak@mail.nih.gov. Collaborative Research Opportunity: The National Chemical Genomics Center is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the assay for detection of genotoxic agents using RPE cell line having hELG1–CFP. Please contact E:\FR\FM\18AUN1.SGM 18AUN1 Federal Register / Vol. 73, No. 160 / Monday, August 18, 2008 / Notices Menghang Xia or James Inglese at mxia@mail.nih.gov or jinglese@mail.nih.gov for more information. August 7, 2008. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E8–18984 Filed 8–19–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings sroberts on PROD1PC70 with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(cX4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Endocrinology, Metabolism, Nutrition and Reproductive Sciences Integrated Review Group; Cellular, Molecular and Integrative Reproduction Study Section. Date: September 15–16, 2008. Time: 8 a.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: Mayflower Park Hotel, 405 Olive Way, Seattle, WA 98101. Contact Person: Stuart B. Moss, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6170, MSC 7892, Bethesda, MD 20892, 301–435– 1044, mossstua@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; CostEffectiveness Research. Date: September 16, 2008. Time: 10 a.m. to 1 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (telephone conference call). Contact Person: Elisabeth Koss, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3152, MSC 7770, Bethesda, MD 20892, (301) 435– 1721, kosse@csr.nih.gov. VerDate Aug<31>2005 16:50 Aug 15, 2008 Jkt 214001 Name of Committee: Center for Scientific Review Special Emphasis Panel; Program Project: Behavioral and Economic Evaluation of Medicare Part D. Date: September 19, 2008. Time: 9 a.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: One Washington Circle Hotel, One Washington Circle, Washington, DC 20037. Contact Person: Valerie Durrant, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3148, MSC 7770, Bethesda, MD 20892, (301) 435– 3554, durrantv@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Stress, Fitness and Obesity. Date: September 29, 2008. Time: 11 a.m. to 1 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015. Contact Person: Michael Micklin, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3136, MSC 7759, Bethesda, MD 20892, (301) 435– 1258, micklinm@csr.nih.gov. Name of Committee: Surgical Sciences, Biomedical Imaging and Bioengineering Integrated Review Group; Biomedical Computing and Health Informatics Study Section. Date: October 2, 2008. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Washington DC/Rockville, 1750 Rockville Pike, Rockville, MD 20852. Contact Person: Bill Bunnag, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5124, MSC 7854, Bethesda, MD 20892, (301) 435– 1177, bunnagb@csr.nih.gov. Name of Committee: Integrative, Functional and Cognitive Neuroscience Integrated Review Group; Neurobiology of Learning and Memory Study Section. Date: October 2–3, 2008. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: One Washington Circle Hotel, One Washington Circle, Washington, DC 20037. Contact Person: Bernard F. Driscoll, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5184, MSC 7844, Bethesda, MD 20892, 301–435– 1242, driscolb@csr.nih.gov. Name of Committee: Digestive Sciences Integrated Review Group; Gastrointestinal Cell and Molecular Biology Study Section. Date: October 2, 2008. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Holiday Inn Express Fisherman’s Wharf, 550 North Point Street, San Francisco, CA 94133. PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 48219 Contact Person: Najma Begum, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2175, MSC 7818, Bethesda, MD 20892, 301–435– 1243, begumn@csr.nih.gov. Name of Committee: Biobehavioral and Behavioral Processes Integrated Review Group; Adult Psychopathology and Disorders of Aging Study Section. Date: October 2–3, 2008. Time: 8 a.m. to 12 p.m. Agenda: To review and evaluate grant applications. Place: Key Bridge Marriott, 1401 Lee Highway, Arlington, VA 22209. Contact Person: Alfonso R. Latoni, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3182, MSC 7848, Bethesda, MD 20892, 301–435– 0913, latonia@csr.nih.gov. Name of Committee: Health of the Population Integrated Review Group; Behavioral Genetics and Epidemiology Study Section. Date: October 2–3, 2008. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hotel Palomar Washington, DC, 2121 P Street, NW., Washington, DC 20037. Contact Person: Elisabeth Koss, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3152, MSC 7770, Bethesda, MD 20892, (301) 435– 1721, kosse@csr.nih.gov. Name of Committee: Integrative, Functional and Cognitive Neuroscience Integrated Review Group; Neurotoxicology and Alcohol Study Section. Date: October 2, 2008. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Latham Hotel, 3000 M Street, NW., Washington, DC 20007. Contact Person: Brian Hoshaw, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5181, MSC 7844, Bethesda, MD 20892, 301–435– 1033, hoshawb@csr.nih.gov. Name of Committee: Molecular, Cellular and Developmental Neuroscience Integrated Review Group; Molecular Neuropharmacology and Signaling Study Section. Date: October 2–3, 2008. Time: 8 a.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: Mayflower Park Hotel, 405 Olive Way, Seattle, WA 98101. Contact Person: Deborah L. Lewis, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4118, MSC 7850, Bethesda, MD 20892, 301–435– 1224, lewisdeb@csr.nih.gov. Name of Committee: Cell Biology Integrated Review Group; Molecular and Integrative Signal Transduction Study Section. E:\FR\FM\18AUN1.SGM 18AUN1

Agencies

[Federal Register Volume 73, Number 160 (Monday, August 18, 2008)]
[Notices]
[Pages 48218-48219]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-18984]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Species-Independent A3 Adenosine Receptor Agonists

    Description of Technology: The A3 adenosine receptor (A3AR) subtype 
has been linked with helping protect the heart from ischemia, 
controlling inflammation, and regulating cell proliferation. Agonists 
of the human A3AR subtype have been described; however, they lack 
selectivity for the corresponding receptor of the mouse. This poses a 
problem for clinical development because animal model testing is 
important for pre-clinical validation of drug function. Consequently, a 
novel agonist was made that is selective for the mouse A3AR while 
retaining selectivity for the human receptor. This innovation should 
facilitate moving A3 agonists into the clinical phase of drug 
development with confidence.
    This invention claims species-independent agonists of A3AR, 
specifically (N)-methanocarba adenine nucleosides. In addition, it 
describes pharmaceutical compositions comprising such nucleosides, and 
methods of use such as administering an effective amount to a mammal.
    Applications: cardiac arrhythmias or ischemia; inflammation; 
stroke; diabetes; asthma; cancer.
    Market: Heart disease and cancer are the leading causes of death 
for both women and men in the United States despite many advances in 
drug development. Hence, there is a need for drugs with unique 
mechanism of action. It is noteworthy that the first synthetic 
adenosine receptor agonist has recently been approved for use in 
humans.
    Development Status: Research quantities of compounds have been 
synthesized and tested for receptor selectivity.
    Inventors: Kenneth A. Jacobson and Artem Melman (NIDDK).
    Publication: A Melman et al. Design of (N)-methanocarba adenosine 
5'-uronamides as species-independent A3 receptor-selective agonists. 
Bioorg Med Chem Lett. 2008 May 1;18(9):2813-2819.
    Patent Status: U.S. Provisional Application No. 61/040,985 filed 31 
Mar 2008 (HHS Reference No. E-140-2008/0-US-01).
    Licensing Status: Available for exclusive or non-exclusive 
licensing.
    Licensing Contact: Norbert Pontzer, J.D., Ph.D.; 301-435-5502; 
pontzern@mail.nih.gov.

Fluorescent Cell Lines for Detection of DNA Damage

    Description of Technology: The Enhanced Level of Genomic 
instability 1 (ELG1) protein suppresses genomic instability caused by 
DNA damage. Cell lines for studying human ELG1 (hELG1) have been 
established that stably express a fusion protein combining hELG1 and 
either Green Fluorescent Protein (GFP) or Cyan Fluorescent Protein 
(CFP). It has been shown that the fluorescent hELG1 is an excellent 
reporter for DNA damage within the cell, with increased hELG1 
localization to the cell nucleus upon exposure to a genotoxin. 
Therefore, these cell lines may have utility as a screening tool to 
detect genotoxic agents.
    Available for licensing are the RPE cell line (immortalized normal 
retinal pigment epithelial cells) stably expressing hELG1-CFP, and the 
U2OS cell line (human osteosarcoma cells) stably expressing hELG1-GFP.
    Applications: High-sensitivity screening tool for genotoxic agents.
    Inventor: Kyungjae Myung (NHGRI).
    Relevant Publication: In preparation.
    Patent Status: DHHS Reference No. E-108-2008/0--Research Tool. 
Patent protection is not being pursued for this technology.
    Licensing Status: Available for non-exclusive licensing.
    Licensing Contact: Tara L. Kirby, Ph.D.; 301-435-4426; 
tarak@mail.nih.gov.
    Collaborative Research Opportunity: The National Chemical Genomics 
Center is seeking statements of capability or interest from parties 
interested in collaborative research to further develop, evaluate, or 
commercialize the assay for detection of genotoxic agents using RPE 
cell line having hELG1-CFP. Please contact

[[Page 48219]]

Menghang Xia or James Inglese at mxia@mail.nih.gov or 
jinglese@mail.nih.gov for more information.

    August 7, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E8-18984 Filed 8-19-08; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.